Skip to main content

Day: February 27, 2024

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided business highlights. “2023 was a year of significant progress across our broad therapeutic portfolio and further clinical validation of our BBB-crossing Transport Vehicle (TV) platform,” said Ryan Watts, Ph.D., Chief Executive Officer of Denali. “In 2024, we expect to complete enrollment of our late-stage trials in MPS II and ALS as we establish commercial readiness for our product candidates in our first...

Continue reading

FirstService Residential Further Enhances Market Leadership Position in Florida

Written by Customer Service on . Posted in Mergers And Acquisitions.

Acquires Rizzetta & Company TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) — FirstService Corporation (TSX and NASDAQ: FSV) (“FirstService”) announced today that FirstService Residential, the North American property management leader, has recently acquired a controlling interest in Rizzetta & Company (“Rizzetta” or the “Company”). William “Bill” Rizzetta, Founder and President, will retain a significant equity stake in the Company and will continue to lead its operations. Terms of the transaction were not disclosed. Based in Tampa, Florida and founded in 1986, Rizzetta is a leading full-service provider of consulting and property management services to homeowner associations and community development districts (“CDDs”) through eight offices across Florida. A CDD is a special-purpose local government district created under Florida...

Continue reading

Cumulus Media Reports Operating Results for 2023

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Launches Debt Exchange for Senior Notes and Term Loan ATLANTA, Feb. 27, 2024 (GLOBE NEWSWIRE) — Cumulus Media Inc. (NASDAQ: CMLS) (the “Company,” “Cumulus Media,” “we,” “us,” or “our”) today announced operating results for the three months and year ended December 31, 2023. Mary G. Berner, President and Chief Executive Officer of Cumulus Media, said, “While 2023 was a tough year across the media landscape, we were able to offset some of the effects of the weak national advertising climate through strong execution in our key focus areas. Specifically, we grew our digital businesses, meaningfully reduced fixed costs, and improved our balance sheet. Looking ahead, though national advertisers are expressing interest in increasing their radio buys, as of yet, ad demand remains choppy, reducing our visibility into the...

Continue reading

Global Digital PCR Market to Surpass 11.97 Billion by 2030 Driven by Rising Need for Sensitive Quantification of Nucleic Acids

Written by Customer Service on . Posted in Mergers And Acquisitions.

SkyQuest projects that the global digital PCR market will attain a value of USD11.97 billion by 2030, with a CAGR of 9.14% during the forecast period (2023-2030). The global digital PCR market is experiencing rapid growth, primarily propelled by the rising need for precise and sensitive quantification and analysis of nucleic acids. Digital PCR has gained prominence due to its ability to provide unmatched accuracy and sensitivity, establishing itself as an indispensable tool in various critical domains. Westford,USA, Feb. 27, 2024 (GLOBE NEWSWIRE) — According to SkyQuest, the primary objective of the global digital PCR market is to offer advanced molecular diagnostic solutions that empower healthcare providers, clinical laboratories, and researchers to access precise and dependable results. These results enhance patient care by...

Continue reading

Intra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care Conference

Written by Customer Service on . Posted in Public Companies.

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024 at 11:10 a.m. ET in Boston, MA. The live and archived webcast can be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software. About Intra-Cellular Therapies Intra-Cellular Therapies is a biopharmaceutical company...

Continue reading

Ardelyx to Participate at the Cowen 44th Annual Health Care Conference

Written by Customer Service on . Posted in Public Companies.

WALTHAM, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Susan Rodriguez, chief commercial officer of Ardelyx, will participate in a Cardiorenal panel discussion at the Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 10:30 A.M. Eastern Time in Boston, MA. To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentations. A replay of the panel presentation will be available on the Ardelyx website for 30 days following the event. About Ardelyx, Inc.Ardelyx was founded with a mission to discover,...

Continue reading

Synchronoss Technologies to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, March 12, 2024 at 4:30 p.m. ET

Written by Customer Service on . Posted in Public Companies.

BRIDGEWATER, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (“Synchronoss” or the “Company”) (Nasdaq: SNCR), a leading global provider of personal cloud software and services, will hold a conference call on Tuesday, March 12, 2024 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss its financial results for the fourth quarter and full year ended December 31, 2023. Financial results will be issued in a press release prior to the call. Synchronoss management will host the presentation, followed by a question-and-answer period. Date: Tuesday, March 12, 2024Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)Registration Link: Click here to register Please register online at least 10 minutes prior to the start time. Upon registration, the webcast platform will provide dial-in numbers and a unique access...

Continue reading

Gentex’s HomeLink Brand Expands To Provide Smart Home & Security Systems

Written by Customer Service on . Posted in Public Companies.

ZEELAND, Mich., Feb. 27, 2024 (GLOBE NEWSWIRE) — Today at the International Builders’ Show, Gentex Corporation (NASDAQ: GNTX) announced the launch of HomeLink Smart Home Solutions, a comprehensive, curated suite of smart home products all controlled and monitored by a single app. The overall goal is to help unite the worlds of car connectivity and home automation into a single, seamless ecosystem. Gentex is a technology company and a long-time supplier of electro-optical products for the global automotive, aerospace, fire protection, and medical industries. It’s best known for supplying nearly every major automaker with connected-car technologies and advanced electronic features that optimize driver vision and enhance driving safety. Gentex’s HomeLink product is the auto industry’s leading car-to-home automation system, consisting...

Continue reading

Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference

Written by Customer Service on . Posted in Public Companies.

WATERTOWN, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) — Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced the company’s president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a panel entitled “Gynecological Cancers Corporate Panel Discussion” on Tuesday, March 5, 2024 at 10:30 a.m. ET at the TD Cowen 44th Annual Health Care Conference in Boston, MA. To access the live webcast, visit the Events & Presentations page within the investor section...

Continue reading

Lancaster Resources Acquires High-Impact Uranium Claims in Athabasca Basin

Written by Customer Service on . Posted in Mergers And Acquisitions.

VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) — Lancaster Resources Inc. (CSE:LCR) (OTCQB:LANRF) (FRA:6UF) (“Lancaster”), Lancaster Resources, a North American critical minerals exploration company, is excited to announce the acquisition of two high impact mineral claims in the world-class Athabasca Basin. The two claims are targeting high grade uranium in basement and unconformity type deposits. The two properties, called Catley Lake and Centennial East, at 3,036 hectares and 5,081 hectares respectively, provide significant exploration opportunities. These strategic acquisitions bolster Lancaster’s commitment to discovering critical minerals in support of the energy transition. The Catley Lake & Centennial East mineral claims are located immediately adjacent to Cameco’s Centennial deposit claim block in...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.